Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Okta, Inc. (OKTA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Okta, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.88 (market cap $4.49B), while Okta, Inc. trades at $145.75 (market cap $25.81B). The key difference: Okta, Inc. is far larger — about 5.7× ACADIA Pharmaceuticals Inc.'s market cap, and Okta, Inc. is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | OKTA | |
|---|---|---|
Market Cap | $4.49B | $25.81B |
Sector | Health | Technology |
52-Week High | $28.06 | $148.60 |
52-Week Low | $20.06 | $62.93 |
Enterprise Value | $3.69B | $23.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
OKTA trades at $148.47, up 4.99% on the day, with strong technical momentum and bullish moving averages. The company reported revenue of $2.61B in 2025, achieving profitability with net income of $28M after years of losses. Recent earnings beats and AI-driven demand have fueled investor optimism, though valuation multiples remain elevated.
Outlook is positive with robust revenue growth and improving margins, but high P/E of 107.68 poses valuation risk. Analyst consensus is bullish with 72.55% buy ratings, though price target of $121.08 suggests caution near current levels. Key risks include competition and execution on AI monetization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
